The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
LENALIDOMIDE VIATRIS (Alphapharm Pty Ltd)
Product name
LENALIDOMIDE VIATRIS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
117 (255 working days)
Active ingredients
Lenalidomide
Registration type
New generic medicine
Indication
LENALIDOMIDE VIATRIS is indicated for the treatment of multiple myeloma.